Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
YAVNE, Israel - MediWound Ltd. (NASDAQ:MDWD), a $201.56 million market cap company specializing in enzymatic therapeutics for tissue repair, announced findings from a post hoc analysis published in the journal Wounds, indicating that its product EscharEx may offer clinical advantages in treating venous leg ulcers (VLUs) over the current FDA-approved treatment, SANTYL. According to InvestingPro data, while the company posted 8.22% revenue growth in the last twelve months, analysts anticipate continued investment phase as the company develops its product pipeline.
The analysis, derived from the company’s Phase II ChronEx trial data, suggests that EscharEx achieved faster and more complete debridement of VLUs compared to patients treated with SANTYL. Complete debridement at two weeks was seen in 63% of patients using EscharEx, versus none in the SANTYL group. Additionally, 50% of EscharEx patients reached complete wound bed preparation within two weeks, compared to none with SANTYL. With the company’s next earnings report due on May 21, 2025, investors following InvestingPro research reports will be watching for updates on the commercialization timeline.
While wound closure rates between the two treatments were not statistically different, EscharEx patients who achieved closure did so in an average of 48 days, versus 76 days for those using SANTYL. The safety profile and tolerability were similar between both groups, with fewer deep wound infections reported in the EscharEx cohort.
EscharEx is a bromelain-based enzymatic therapy designed for once-daily topical application. It has shown effectiveness in removing non-viable tissue and promoting granulation, which are critical for optimal wound bed preparation. Currently, a global Phase III study in VLUs is underway, with a diabetic foot ulcers (DFUs) study in preparation.
MediWound’s existing FDA-approved product, NexoBrid, is marketed for eschar removal in thermal burns across the U.S., European Union, Japan, and other markets. The company continues to focus on developing treatments for non-surgical tissue repair and is exploring a substantial market opportunity with EscharEx.
This announcement is based on a press release statement and provides insights into the potential clinical benefits of EscharEx in comparison to SANTYL, offering a new therapeutic option for healthcare providers managing chronic and hard-to-heal wounds. MediWound’s research efforts underscore its commitment to addressing unmet needs in wound care through innovative enzymatic solutions. Investors seeking deeper insights can access comprehensive analysis and 6 additional ProTips through InvestingPro, which offers exclusive financial health scores and detailed valuation metrics for over 1,400 US stocks.
In other recent news, MediWound Ltd reported its fourth-quarter 2024 earnings, exceeding expectations with an EPS of -0.36 against a projected -0.56. The company’s revenue for the quarter was $5.84 million, slightly above the forecast of $5.83 million. For the full year, MediWound’s total revenue increased to $20.2 million from $18.7 million in 2023. Despite these positive results, the company faced a net loss of $30.2 million, or $3.03 per share. The company continues to focus on strategic product developments and partnerships to strengthen its market position. MediWound is also advancing clinical trials, including the Phase 3 VLU Global Trial for EscharEx. Looking ahead, the company projects NexoBrid’s 2025 revenue to reach $24 million. MediWound’s cash position at the year-end stood at $43.6 million, providing a robust foundation for future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.